Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U. Robak T, et al. Br J Haematol. 2017 Feb;176(4):618-628. doi: 10.1111/bjh.14464. Epub 2016 Dec 15. Br J Haematol. 2017. PMID: 27977057 Free PMC article. Clinical Trial.
Molnupiravir is effective in patients with haematological malignancies.
Bołkun Ł, Pula B, Kołkowska-Leśniak A, Morawska M, Cichocka E, Charlinski G, Garus B, Giebel S, Piszcz J, Drozd-Sokolowska J, Kwiatkowski J, Biernat M, Hus I, Lech-Maranda E, Długosz-Danecka M, Giannopoulos K, Wróbel T. Bołkun Ł, et al. Int J Cancer. 2023 Sep 15;153(6):1251-1256. doi: 10.1002/ijc.34442. Epub 2023 Feb 7. Int J Cancer. 2023. PMID: 36691818
Prognostic Impact of Copy Number Alterations' Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy.
Libura M, Karabin K, Tyrna P, Czyż A, Makuch-Łasica H, Jaźwiec B, Paluszewska M, Piątkowska-Jakubas B, Zawada M, Gniot M, Trubicka J, Szymańska M, Borg K, Więsik M, Czekalska S, Florek I, Król M, Paszkowska-Kowalewska M, Gil L, Kapelko-Słowik K, Patkowska E, Tomaszewska A, Mądry K, Machowicz R, Czerw T, Piekarska A, Dutka M, Kopińska A, Helbig G, Gromek T, Lewandowski K, Zacharczuk M, Pastwińska A, Wróbel T, Haus O, Basak G, Hołowiecki J, Juszczyński P, Lech-Marańda E, Giebel S, Jędrzejczak WW. Libura M, et al. Among authors: lech maranda e. Cancers (Basel). 2023 Nov 15;15(22):5431. doi: 10.3390/cancers15225431. Cancers (Basel). 2023. PMID: 38001691 Free PMC article.
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K; Polish Adult Leukemia Group. Wrzesień-Kuś A, et al. Eur J Haematol. 2003 Sep;71(3):155-62. doi: 10.1034/j.1600-0609.2003.00122.x. Eur J Haematol. 2003. PMID: 12930315 Clinical Trial.
124 results